Last reviewed · How we verify
Tafamidis Pill
Tafamidis Pill is a Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved.
Tafamidis is a small molecule that stabilizes transthyretin, a protein associated with Transthyretin Amyloidosis. It is used to treat Transthyretin Amyloidosis, specifically Transthyretin Amyloid Polyneuropathy, as indicated by clinical trials.
At a glance
| Generic name | Tafamidis Pill |
|---|---|
| Sponsor | Peking University Third Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafamidis Pill CI brief — competitive landscape report
- Tafamidis Pill updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Tafamidis Pill
What is Tafamidis Pill?
Who makes Tafamidis Pill?
What development phase is Tafamidis Pill in?
Related
- Manufacturer: Peking University Third Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing